Integrative analysis of multi‐omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer

Background:Lung cancers or (Bronchogenic-Carcinomas) are the disease in certain parts of the lungs in which irresistible multiplication of abnormal cells leads to the inception of a tumor. Lung cancers consisting of two substantial forms based on the microscopic appearance of tumor cells are: Non-Small-Cell-Lung-Cancer (NSCLC) (80 to 85%) and Small-Cell-Lung-Cancer (SCLC) (15 to 20%).Discussion:Lung cancers are existing luxuriantly across the globe and the most prominent cause of death in advanced countries (USA & UK). There are many causes of lung cancers in which the utmost imperative aspect is the cigarette smoking. During the early stage, there is no perspicuous sign/symptoms but later many symptoms emerge in the infected individual such as insomnia, headache, pain, loss of appetite, fatigue, coughing etc. Lung cancers can be diagnosed in many ways, such as history, physical examination, chest X-rays and biopsy. However, after the diagnosis and confirmation of lung carcinoma, various treatment approaches are existing for curing of cancer in different stages such as surgery, radiation therapy, chemotherapy, and immune therapy. Currently, novel techniques merged that revealed advancements in detection and curing of lung cancer in which mainly includes: microarray analysis, gene expression profiling.Conclusion:Consequently, the purpose of the current analysis is to specify and epitomize the novel literature pertaining to the development of cancerous cells in different parts of the lung, various preeminent approaches of prevention, efficient diagnostic procedure, and treatments along with novel technologies for inhibition of cancerous cell growth in advance stages.

Download Full-text

First prospective study of a combined immune therapy of checkpoint inhibitors ± CTX plus Viscum album L. in non-small cell lung cancer (NSCLC) in UICC stage III B-IV B

Phytomedicine ◽

10.1016/j.phymed.2019.09.130 ◽

2019 ◽

Vol 61 ◽

pp. 6-7

Author(s):

Christian Grah ◽

Klaudia Kunc ◽

Burkhard Matthes ◽

Annette Kurzeja ◽

Arne Müssig ◽

...

Keyword(s):

Lung Cancer ◽

Prospective Study ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Checkpoint Inhibitors ◽

Immune Therapy ◽

Viscum Album ◽

Small Cell ◽

Uicc Stage ◽

Small Cell Lung

Download Full-text

Integrative analysis of microRNA and mRNA expression profiles in non-small-cell lung cancer

Cancer Gene Therapy ◽

10.1038/cgt.2016.5 ◽

2016 ◽

Vol 23 (4) ◽

pp. 90-97 ◽

Cited By ~ 27

Author(s):

C Yang ◽

C Sun ◽

X Liang ◽

S Xie ◽

J Huang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Mrna Expression ◽

Cell Lung Cancer ◽

Expression Profiles ◽

Small Cell ◽

Integrative Analysis ◽

Small Cell Lung

Download Full-text

OR.88. IL-7/IL-7R alpha-Fc Immune Therapy for Non Small Cell Lung Cancer

Clinical Immunology ◽

10.1016/j.clim.2008.03.095 ◽

2008 ◽

Vol 127 ◽

pp. S36

Author(s):

Asa Andersson ◽

Anshu Buttan ◽

Raj Batra ◽

Li Zhu ◽

Steven Dubinett ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Immune Therapy ◽

Small Cell ◽

Small Cell Lung

Download Full-text

Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer

10.21203/rs.3.rs-148857/v1 ◽

2021 ◽

Author(s):

Yabin Chen ◽

Zhaoyuan Fang ◽

Ying Tang ◽

Yujuan Jin ◽

Chenchen Guo ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Immune Therapy ◽

Small Cell ◽

Rna Seq ◽

Small Cell Lung ◽

Machine Learning Model ◽

Novel Variant ◽

Genomic Studies

Abstract Small cell lung cancer (SCLC) is highly invasive and lethal. Genomic studies are beginning to characterize its genetic determinants and heterogeneity. Here we performed RNA-Seq and whoe exome sequencing (WES) in 19 Chinese SCLC clinical tumor specimens. Integration with other two public cohorts (n = 129 for RNA-seq, n = 171 for WES), we carried out gene co-expression network analysis and classified into four subgroups: ASCL1-high, NEUROD1-high, a novel variant subtype with CCSP/CC10-high, and a fourth subtype with high expression of NOTCH family and inflammatory genes. We further found that this fourth subtype was characterized by overexpression of immune-related pathways and immunosuppressive factors, referred to as immune subtype. In addition to transcriptomic signatures, specific genomic alterations were also significantly enriched in each subtype. We successfully built a machine learning model to predict the subtypes of newly coming specimens based on transcriptomic data. In particular, we found that POU2F3 protein was effective in distinguishing immunotherapy patients, i.e. the immune subtype, which was further validated by an independent data of chemo-resistant patients received 2nd -line immunotherapy. Collectively, our work systematically studied the transcriptomic and genomic heterogeneity of SCLC, and characterized an immune subtype that displayed features of sensitivity to immune checkpoint-based therapies.

Download Full-text

LAG-3 and PD-1/PD-L1 inhibitors might become a promising treatment for small cell lung cancer

10.21203/rs.3.rs-48482/v1 ◽

2020 ◽

Author(s):

Yi Xu ◽

Liping Zhang ◽

Shengyu Wu ◽

Wei Zhang ◽

Yu Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Immune Therapy ◽

Small Cell ◽

Small Cell Lung ◽

Programmed Death ◽

Programmed Death 1 ◽

Promising Treatment ◽

Spss Software

Abstract Background Immune therapy has achieved notable success in cancer treatment. A novel immunocheckpoint, Lymphocyte activing gene-3 (LAG-3), has shown promising therapeutic efficacy in non-small cell lung cancer (NSCLC). However, literature about LAG-3 in small cell lung cancer (SCLC) is scarce. We performed statistical analysis to explore LAG-3 expression in SCLC patients, the correlation with programmed death 1 (PD-1) and programmed death ligand 1 (PD-1), the survival predictive significance, and the possibility of becoming an immunotherapeutic checkpoint of SCLC.Methods In this study, we included 102 patients diagnosed with SCLC. The expression of protein was evaluated by immunohistochemistry (IHC) staining. We performed all the correlation analysis and survival analysis with SPSS software (version 17.0; SPSS, Inc.; Chicago, IL)Results In SCLC, none tumor cell expressed LAG-3. LAG-3-positive TILs existed in 39.2% patients. The expression of LAG-3 was remarkably associated to PD-1 and PD-L1 expression on TILs (p = 0.006, p = 0.001). LAG-3 was the only prediction for TILs PD-L1 expression (ORs = 0.161, 95% CI: 0.063–0.412, p < 0.01). Although LAG-3-positive patients had relatively longer RFS, LAG-3 expression had no statistically significant differences in predicting prognosis (p = 0.088).Conclusions LAG-3 is an important immune checkpoint closely related to PD-1/PD-L1. There was significant correlation of LAG-3, PD-1, PD-L1 expression. LAG-3 and PD-1/PD-L1 inhibitors might be a promising immune therapy for SCLC.

Download Full-text